Publications by authors named "Chuanliang Cui"
Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial.
Signal Transduct Target Ther
November 2024
Neoadjuvant PD-1 inhibitor is promising in cutaneous melanoma but remains unknown in acral melanoma (AM). This phase Ib trial study (Clinicaltrials.gov NCT04197882) assessed the efficacy and safety of the combination of neoadjuvant oncolytic virus orienX010 (ori) and anti-PD-1 toripalimab (tori) for resectable AM.
View Article and Find Full Text PDFArticle Synopsis
- - The study assessed the safety and efficacy of the anti-PD-L1 antibody Socazolimab combined with nab-paclitaxel as a first-line treatment for advanced urothelial carcinoma (aUC), which is crucial for patients who cannot tolerate platinum-based therapies.
- - In a multi-center phase Ib trial involving 20 patients, the combination treatment was found to be generally well-tolerated, with most adverse effects being mild (grade 1 or 2) and no severe toxicity (grade 4-5) reported.
- - The results showed an objective response rate of 58.8% and a median progression-free survival of 8.3 months, indicating promising effectiveness for the treatment combination. *
Article Synopsis
- HBM4003 is a new heavy chain-only antibody designed to work with anti-PD-1 antibody toripalimab, aiming to treat advanced solid tumors like melanoma while maintaining safety.* -
- In a phase I trial involving 40 patients, 90% experienced some treatment-related adverse events, but no severe complications (grade 4 or 5) were reported; the treatment showed varying efficacy based on prior PD-1 treatment.* -
- Results indicated an objective response rate of 33.3% for treatment-naïve melanoma patients, and baseline Treg/CD4+ ratio was identified as a potential predictor of treatment efficacy.*
Article Synopsis
- A study focused on patients with advanced melanoma undergoing anti-PD-1 monotherapy aimed to identify and analyze hyperprogressive disease (HPD), which affects a minority subset of immunotherapy patients.
- The research evaluated the incidence of HPD using four established definitions and found the Delta TGR > 100 definition to be most effective in predicting poorer outcomes.
- Results showed that HPD occurred in various subtypes, with mucosal melanoma having the highest prevalence, and the presence of multiple metastatic organs significantly increased the risk of experiencing HPD.
IBI310 is a recombinant fully human IgG1 antibody against cytotoxic T lymphocyte antigen 4. This study was conducted to evaluate IBI310 monotherapy or combination therapy with sintilimab in the patients with advanced melanoma or urothelial carcinoma (UC). Patients in phase 1a received IBI310 at 0.
View Article and Find Full Text PDFPurpose: Mucosal melanoma of the nasal cavity and paranasal sinuses (NPMM) is a highly aggressive disease. The role of postoperative adjuvant radiation therapy is controversial.
Methods And Materials: A total of 300 patients with NPMM treated between March 2009 and January 2020 were divided into surgery alone (SA; 158 patients) and surgery plus radiation therapy (SR; 142 patients) groups.
Article Synopsis
- Bone metastasis (BM) in renal cell carcinoma (RCC) is linked to a poor prognosis, but there's uncertainty on how to treat patients with only bone metastases.
- A study at Peking University Cancer Hospital analyzed data from 54 RCC patients with bone-only metastases, revealing that many faced disease progression with a median progression-free survival (PFS) of 16.2 months and overall survival (OS) of 65.2 months.
- Results indicated that patients with fewer metastatic sites had better outcomes, and factors like the number of metastasis sites and certain RCC characteristics can help predict survival and influence treatment options.
Introduction: Pembrolizumab is well-tolerated in pediatric patients with advanced tumors, consistent with results in adults. However, information on the safety and efficacy of adjuvant pembrolizumab in children and adolescents with melanoma is lacking.
Objectives: To compare pembrolizumab versus high-dose interferon-α2b (HDI) as adjuvant therapy in pediatric patients with melanoma.
Article Synopsis
- The study investigated the combination of sitravatinib and tislelizumab in patients with advanced melanoma who had previously progressed on anti-PD-(L)1 therapy.
- It was an open-label, multicenter trial with 25 participants, focusing on the safety and tolerability of the treatment.
- Results showed that while 52% of patients experienced serious treatment-emergent adverse events, most were manageable, and there was a promising 36% objective response rate along with a median progression-free survival of 6.7 months.
Phase Ib study of anlotinib in combination with anti-PD-L1 antibody (TQB2450) in patients with advanced acral melanoma.
J Eur Acad Dermatol Venereol
January 2024
Background: Acral melanoma, the most common subtype of melanoma in Asians, is often diagnosed at an advanced stage and responds poorly to current programmed cell death protein 1 (PD-1) inhibitors.
Objectives: To evaluate the safety and efficacy of TQB2450 and anlotinib in patients with advanced acral melanoma in a phase Ib study (NCT03991975).
Methods: Patients received TQB2450 (1200 mg every 3 weeks) and anlotinib (10 mg or 12 mg once daily, 2-week on/1-week off) in the dose-escalation and dose-expansion phases.
A nomogram incorporating Ki67 to predict survival of acral melanoma.
J Cancer Res Clin Oncol
November 2023
Background: The proliferation marker Ki67 is associated with the progression and prognosis of melanoma. However, its prognostic impact on acral melanoma (AM) remains unclear.
Methods: A total of 314 AM patients were enrolled from a cohort of 5758 patients with melanoma at Peking University Cancer Hospital between 2006 and 2018.
Importance: Acral melanoma, known for low tumor mutation burden, responds poorly to immunotherapy. A standard therapy is still lacking.
Objective: To investigate the activity and safety of camrelizumab (an anti-programmed cell death-1 antibody) plus apatinib (a vascular endothelial growth factor receptor 2 inhibitor) and temozolomide as first-line treatment in patients with advanced acral melanoma.
Background: The frequency of HER2 overexpression in bladder cancer is reported as 9%-61%. HER2 alteration correlates with aggressive disease in bladder cancer. Traditional anti-HER2 targeted therapy has failed to show clinical benefits in patients with advanced urothelial carcinoma .
View Article and Find Full Text PDFBackground: Human epidermal growth factor receptor 2 (HER2) overexpression is related to anti-HER2 therapy in many tumors. RC48- antibody-drug conjugate (ADC) has shown promising efficacy in patients with HER2-positive locally advanced or metastatic urothelial carcinoma (UC). The characteristic expression and scoring systems of HER2 are nonexistent in UC.
View Article and Find Full Text PDFArticle Synopsis
- Aphase II trial investigated the combination of apatinib and camrelizumab for advanced acral melanoma, as current treatments are inadequate and no standard exists.
- Out of 30 participants, the objective response rate was 24.1%, with an 82.8% disease control rate and median progression-free survival of 7.39 months.
- The treatment was associated with manageable side effects, mainly grade 3-4 toxicities like transaminase elevations and leukocytopenia, but no treatment-related deaths occurred.
Background: Pucotenlimab is a novel recombinant humanized anti-PD-1 (Programmed death-1) monoclonal antibody, which belongs to the human IgG4/kappa subtype, and can selectively block the binding of PD-1 with its ligands PD-L1 and PD-L2.
Methods: In this phase 2 trial, patients with locally advanced or metastatic melanoma who had failed conventional treatment (chemotherapy, targeted therapy, interferon, IL-2, et al.) were recruited.
Background: Acral melanoma (AM) is less responsive to immunotherapy than nonacral cutaneous melanoma. Variable responses are seen during immunotherapy, including pseudoprogression, hyperprogressive disease (HPD) and heterogeneous responses. There are currently no studies on the response patterns of patients with AM treated with immunotherapy and the impact on the outcome.
View Article and Find Full Text PDFBackground: Accumulating data suggest that mucosal melanoma, well known for its poor response to immune checkpoint blockade (ICB) and abysmal prognosis, is a heterogeneous subtype of melanoma with distinct genomic and clinical characteristics between different anatomic locations of the primary lesions. Primary malignant melanoma of the esophagus (PMME) is a rare, highly aggressive disease with a poorer prognosis compared with that of non-esophageal mucosal melanoma (NEMM). In this study, we retrospectively analyzed the efficacy of anti-programmed death (PD)-1 in patients with PMME and explored its molecular basis.
View Article and Find Full Text PDFArticle Synopsis
- Single-cell technologies are key for analyzing immune cell interactions in tumors, which helps us understand cancer progression and treatment resistance, particularly in melanoma patients undergoing anti-PD-1 therapy.
- Using advanced imaging mass cytometry, researchers quantified 35 proteins and profiled over 662,000 cells from tumor tissues to identify various cell types and their spatial relationships within different tumor microenvironments (TMEs).
- The study found that diverse TME archetypes were linked to varying responses to anti-PD-1 therapy, and gene expression signatures from these archetypes could effectively predict patient outcomes across multiple cohorts.
Purpose: Few studies focused on the incidence of brain metastasis in patients with acral and mucosal melanoma, and a better understanding of the incidences and predictors of brain metastasis is needed in these patients.
Method: A prospectively accrued cohort of 799 patients with acral and mucosal melanoma in stages I-III from July 2011 to December 2015 at Peking University Cancer Hospital were included in this study. Competing risk models (Fine and Gray) were used to estimate the cumulative incidence of brain metastasis and compare the differences in cumulative incidence curves between different primary lesions, stages, and molecular types.
Prognostic impact of Breslow thickness in acral melanoma: A retrospective analysis.
J Am Acad Dermatol
December 2022
Background: Evidence for the prognostic importance of tumor thickness in acral melanoma (AM) patients is limited.
Objective: The objective of the study was to determine the prognostic impact of Breslow thickness in AM.
Methods: This multicenter study enrolled patients diagnosed with localized AM between January 1, 2000 and December 31, 2017.
Background: Adjuvant chemotherapy has been shown to produce a favorable prognosis for patients with resectable mucosal melanoma (MM), resulting in the need for stratification to optimally select patients to benefit from adjuvant therapy. This study analyzed Ki67 as a potential stratification index for adjuvant chemotherapy in resectable MM.
Methods: Patients with resected MM who received subsequent adjuvant therapy in Beijing Cancer Hospital between 2010 and 2018 were retrospectively enrolled and analyzed.
Objective: To investigate the clinicopathological characteristics, response to different treatment regimens, and prognostic factors of metastatic collecting duct carcinoma (CDC).
Patients And Methods: Information of patients with metastatic CDC was retrieved from a database including clinical and survival data. Survival outcomes were analyzed with the Kaplan-Meier method, and prognostic factors were identified with the Cox proportional hazard model.
Background: Anti-programmed cell death receptor-1 (PD-1) monotherapy is the standard treatment for metastatic melanoma in current. Camrelizumab is a humanized IgG4 anti-PD-1 monoclonal antibody whose safety and efficacy have not been reported in advanced Asian melanoma patients.
Methods: This phase I study investigated the safety, activity, and pharmacokinetics of camrelizumab in Chinese patients with advanced melanoma.